Successful reintroduction of statin therapy after statin-associated rhabdomyolysis

J Clin Lipidol. 2015 Jul-Aug;9(4):594-6. doi: 10.1016/j.jacl.2015.03.005. Epub 2015 Mar 28.


The case report demonstrates the successful use of an alternative statin after a statin-related episode of rhabdomyolysis. Statin-associated rhabdomyolysis is a serious adverse event with a very low incidence and is considered the most severe of the muscle-related side effects of the statins. Rechallenge with statins is not a recommended practice after rhabdomyolysis. The patient experienced a myocardial infarct 1 y after the episode of rhabdomyolysis. He used alternative lipid-lowering therapy for 2 y. His low-density lipoprotein cholesterol was not meeting typical secondary prevention targets. An alternative statin was introduced and the patient has been followed for 4 years without recurrence of the rhabdomyolysis. This case suggests it may be time to reconsider the accepted practice of permanently avoiding statin therapy after rhabdomyolysis.

Keywords: Creatine kinase; HMG-CoA reductase inhibitors; Hyperlipidemia; Rhabdomyolysis; Serious adverse event; Statin.

Publication types

  • Case Reports

MeSH terms

  • Atorvastatin / administration & dosage
  • Atorvastatin / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Humans
  • Lipids / blood
  • Male
  • Middle Aged
  • Myocardial Infarction / chemically induced
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / etiology
  • Myocardial Infarction / pathology
  • Rhabdomyolysis / blood
  • Rhabdomyolysis / chemically induced*
  • Rhabdomyolysis / drug therapy
  • Rhabdomyolysis / pathology
  • Rosuvastatin Calcium / administration & dosage


  • Lipids
  • Rosuvastatin Calcium
  • Atorvastatin

Supplementary concepts

  • Rhabdomyolysis, Cerivastatin-Induced